Genta assesses direction after disappointing melanoma trial
This article was originally published in Scrip
Genta's troubled novel antisense lead drug candidate Genasense (oblimersen sodium) has failed to meet one of its primary endpoints, progression-free survival (PFS), in a pivotal, first-line Phase III AGENDA trial in advanced melanoma. The company said it was assessing the impact of these data – which will preclude a filing this year – on its strategic direction. Overall survival data will not be mature for another year or so.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.